```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "H",
          "position": "1398"
        },
        "variant_string_id": "LRRK2 R1398H"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses LRRK2 variants and their association with Parkinson's disease (PD), a neurodegenerative disorder characterized by the loss of dopaminergic neurons. LRRK2 is a kinase, and its activity is implicated in PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper establishes the role of LRRK2 in PD and suggests that altered kinase activity of LRRK2 variants can affect disease risk.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses kinase activity assays to assess the impact of LRRK2 variants on its enzymatic function. This directly relates to the disease mechanism, as PD pathogenesis is linked to LRRK2 kinase activity.",
          "judgment": "Yes",
          "reasoning": "Kinase activity assays are directly relevant for assessing how LRRK2 variants impact its function as a kinase in the context of PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study included a 'no kinase' control, and wild-type LRRK2 was used as a comparator. The experiments were performed with n=4.",
          "judgment": "Yes",
          "reasoning": "The study used both 'Normal/Negative/Wild type' (WT LRRK2) and 'Abnormal/Positive/Null' ('no kinase' control). Experiments were performed in replicates (n=4).",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study did not explicitly state that known pathogenic or benign variants were used as controls.",
          "judgment": "No",
          "reasoning": "The paper does not specify the use of previously classified pathogenic or benign variants as controls in their kinase assays.",
          "next_step_or_outcome": "The functional evidence strength is Max BS3_supporting"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The paper indicates that the kinase activities were quantified as fold increase in MPU (mean pixel unit) ± SD and that statistical significance was assessed with specific p-values noted.",
          "judgment": "No",
          "reasoning": "While the study provides statistical analyses (p-values), it does not calculate or provide sufficient data to calculate an OddsPath. Therefore, we cannot proceed to step 4c.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not explicitly state the use of other benign/pathogenic variants as controls",
          "judgment": "10 or less",
          "reasoning": "As pathogenic and benign controls were not mentioned, we assume low control usage.",
          "next_step_or_outcome": "The functional evidence strength is Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_supporting"
      },
      "overall_conclusion": "The R1398H variant showed significantly lower kinase activity compared to wild type, supporting a possible protective (benign) role.  This is capped at BS3_supporting due to the lack of variant controls and the fact OddsPath was not calculated."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "S",
          "alt": "T",
          "position": "1647"
        },
        "variant_string_id": "LRRK2 S1647T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses LRRK2 variants and their association with Parkinson's disease (PD), a neurodegenerative disorder characterized by the loss of dopaminergic neurons. LRRK2 is a kinase, and its activity is implicated in PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper establishes the role of LRRK2 in PD and suggests that altered kinase activity of LRRK2 variants can affect disease risk.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses kinase activity assays to assess the impact of LRRK2 variants on its enzymatic function. This directly relates to the disease mechanism, as PD pathogenesis is linked to LRRK2 kinase activity.",
          "judgment": "Yes",
          "reasoning": "Kinase activity assays are directly relevant for assessing how LRRK2 variants impact its function as a kinase in the context of PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study included a 'no kinase' control, and wild-type LRRK2 was used as a comparator. The experiments were performed with n=4.",
          "judgment": "Yes",
          "reasoning": "The study used both 'Normal/Negative/Wild type' (WT LRRK2) and 'Abnormal/Positive/Null' ('no kinase' control). Experiments were performed in replicates (n=4).",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study did not explicitly state that known pathogenic or benign variants were used as controls.",
          "judgment": "No",
          "reasoning": "The paper does not specify the use of previously classified pathogenic or benign variants as controls in their kinase assays.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The paper indicates that the kinase activities were quantified as fold increase in MPU (mean pixel unit) ± SD and that statistical significance was assessed with specific p-values noted.",
          "judgment": "No",
          "reasoning": "While the study provides statistical analyses (p-values), it does not calculate or provide sufficient data to calculate an OddsPath. Therefore, we cannot proceed to step 4c.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not explicitly state the use of other benign/pathogenic variants as controls",
          "judgment": "10 or less",
          "reasoning": "As pathogenic and benign controls were not mentioned, we assume low control usage.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The in vitro kinase activity of LRRK2 S1647T activity was similar to wild type.  Although there was evidence of association of LRRK2 S1647T as risk factor in the cohort, the data does not support a change in function.  Due to limited evidence, this is capped at PS3_supporting as no OddsPath was calculated."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "P",
          "position": "1628"
        },
        "variant_string_id": "LRRK2 R1628P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses LRRK2 variants and their association with Parkinson's disease (PD), a neurodegenerative disorder characterized by the loss of dopaminergic neurons. LRRK2 is a kinase, and its activity is implicated in PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper establishes the role of LRRK2 in PD and suggests that altered kinase activity of LRRK2 variants can affect disease risk.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses kinase activity assays to assess the impact of LRRK2 variants on its enzymatic function. This directly relates to the disease mechanism, as PD pathogenesis is linked to LRRK2 kinase activity.",
          "judgment": "Yes",
          "reasoning": "Kinase activity assays are directly relevant for assessing how LRRK2 variants impact its function as a kinase in the context of PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study included a 'no kinase' control, and wild-type LRRK2 was used as a comparator. The experiments were performed with n=4.",
          "judgment": "Yes",
          "reasoning": "The study used both 'Normal/Negative/Wild type' (WT LRRK2) and 'Abnormal/Positive/Null' ('no kinase' control). Experiments were performed in replicates (n=4).",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study did not explicitly state that known pathogenic or benign variants were used as controls.",
          "judgment": "No",
          "reasoning": "The paper does not specify the use of previously classified pathogenic or benign variants as controls in their kinase assays.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The paper indicates that the kinase activities were quantified as fold increase in MPU (mean pixel unit) ± SD and that statistical significance was assessed with specific p-values noted.",
          "judgment": "No",
          "reasoning": "While the study provides statistical analyses (p-values), it does not calculate or provide sufficient data to calculate an OddsPath. Therefore, we cannot proceed to step 4c.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not explicitly state the use of other benign/pathogenic variants as controls",
          "judgment": "10 or less",
          "reasoning": "As pathogenic and benign controls were not mentioned, we assume low control usage.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The LRRK2 R1628P showed increased autokinase activity and an increase in MBP phosphorylation compared to the control, suggesting a pathogenic role. Due to the lack of a direct OddsPath calculation, this is capped at PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "R",
          "position": "2385"
        },
        "variant_string_id": "LRRK2 G2385R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses LRRK2 variants and their association with Parkinson's disease (PD), a neurodegenerative disorder characterized by the loss of dopaminergic neurons. LRRK2 is a kinase, and its activity is implicated in PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper establishes the role of LRRK2 in PD and suggests that altered kinase activity of LRRK2 variants can affect disease risk.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses kinase activity assays to assess the impact of LRRK2 variants on its enzymatic function. This directly relates to the disease mechanism, as PD pathogenesis is linked to LRRK2 kinase activity.",
          "judgment": "Yes",
          "reasoning": "Kinase activity assays are directly relevant for assessing how LRRK2 variants impact its function as a kinase in the context of PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study included a 'no kinase' control, and wild-type LRRK2 was used as a comparator. The experiments were performed with n=4.",
          "judgment": "Yes",
          "reasoning": "The study used both 'Normal/Negative/Wild type' (WT LRRK2) and 'Abnormal/Positive/Null' ('no kinase' control). Experiments were performed in replicates (n=4).",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study did not explicitly state that known pathogenic or benign variants were used as controls.",
          "judgment": "No",
          "reasoning": "The paper does not specify the use of previously classified pathogenic or benign variants as controls in their kinase assays.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The paper indicates that the kinase activities were quantified as fold increase in MPU (mean pixel unit) ± SD and that statistical significance was assessed with specific p-values noted.",
          "judgment": "No",
          "reasoning": "While the study provides statistical analyses (p-values), it does not calculate or provide sufficient data to calculate an OddsPath. Therefore, we cannot proceed to step 4c.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not explicitly state the use of other benign/pathogenic variants as controls",
          "judgment": "10 or less",
          "reasoning": "As pathogenic and benign controls were not mentioned, we assume low control usage.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The LRRK2 G2385R showed increased autokinase activity and an increase in MBP phosphorylation compared to the control, suggesting a pathogenic role. Due to the lack of a direct OddsPath calculation, this is capped at PS3_supporting."
      }
    },
    {
       "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "N",
          "alt": "K",
          "position": "551"
        },
        "variant_string_id": "LRRK2 N551K"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses LRRK2 variants and their association with Parkinson's disease (PD), a neurodegenerative disorder characterized by the loss of dopaminergic neurons. LRRK2 is a kinase, and its activity is implicated in PD pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper establishes the role of LRRK2 in PD and suggests that altered kinase activity of LRRK2 variants can affect disease risk.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses kinase activity assays to assess the impact of LRRK2 variants on its enzymatic function. This directly relates to the disease mechanism, as PD pathogenesis is linked to LRRK2 kinase activity.",
          "judgment": "Yes",
          "reasoning": "Kinase activity assays are directly relevant for assessing how LRRK2 variants impact its function as a kinase in the context of PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study included a 'no kinase' control, and wild-type LRRK2 was used as a comparator. The experiments were performed with n=4.",
          "judgment": "Yes",
          "reasoning": "The study used both 'Normal/Negative/Wild type' (WT LRRK2) and 'Abnormal/Positive/Null' ('no kinase' control). Experiments were performed in replicates (n=4).",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study did not explicitly state that known pathogenic or benign variants were used as controls.",
          "judgment": "No",
          "reasoning": "The paper does not specify the use of previously classified pathogenic or benign variants as controls in their kinase assays.",
          "next_step_or_outcome": "The functional evidence strength is Max BS3_supporting"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "The paper indicates that the kinase activities were quantified as fold increase in MPU (mean pixel unit) ± SD and that statistical significance was assessed with specific p-values noted.",
          "judgment": "No",
          "reasoning": "While the study provides statistical analyses (p-values), it does not calculate or provide sufficient data to calculate an OddsPath. Therefore, we cannot proceed to step 4c.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study does not explicitly state the use of other benign/pathogenic variants as controls",
          "judgment": "10 or less",
          "reasoning": "As pathogenic and benign controls were not mentioned, we assume low control usage.",
          "next_step_or_outcome": "The functional evidence strength is Max BS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_supporting"
      },
      "overall_conclusion": "While no functional data was presented for this variant, based on the clinical findings in the paper, R1398H is a possible benign variant.  This is capped at BS3_supporting due to the lack of variant controls and the fact OddsPath was not calculated."
    }
  ]
}
```